
Switzerland shows sustained growth of biotech sector
Capital investments in Swiss biotech companies reached the second-best amount ever with CHF3.33bn in the second year of the pandemic, according to...

XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...

Hansa Biopharma’s imlifidase advances to Phase III testing
According to Lund-based Hansa Biopharma AB the study protocol has been greenlighted both by the FDA and the European Medicines Agency (EMA), so its...

CSL Behring files for MAA of haemophilia B gene therapy
Marburg-based CSL Behring has filed for accelerated EU marketing authorisation of Etranacogene dezaparvovec (EtranaDez), the first haemophilia B gene...

Avantium closes financing for FDCA plant
Polyethylene furanoate (PEF) is 100% fossil-free when made from 2,5-furandicarboxylic acid (FDCA) with fructose as a carbon source und...

Bayer Leaps to invests €1.3bn externally
"We are on the threshold of a new era of innovation in the life sciences." commented Werner Baumann, Chairman of the Board at Bayer...

EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...